Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 68.78% is 1090% above its 5-year average of 5.78%, near the high end of its 5-year range (0.01%–68.78%).
As of the fiscal period ended Tuesday, June 30, 2026. 159.16% above its 12-month average of 26.54%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 68.78%.
DEBT TO ASSETS RATIO
68.78%
DEBT TO ASSETS RATIO AVG TTM
26.54%
DEBT TO ASSETS RATIO AVG 3Y
0.16%
DEBT TO ASSETS RATIO AVG 5Y
5.78%
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+159.16%
CURRENT VS 3Y AVG
+43296.67%
CURRENT VS 5Y AVG
+1090.43%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.09%
median of 874 covered companies
CURRENT VS SECTOR MEDIAN
+76322.37%
vs the sector median at left
ARS Pharmaceuticals, Inc.
Market Cap
$426.51M
Debt to Assets Ratio
68.78%
TTM Avg
26.54%
3Y Avg
0.16%
5Y Avg
5.78%
Market Cap
$422.86M
Debt to Assets Ratio
0.02%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$422.72M
Debt to Assets Ratio
0.17%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$419.87M
Debt to Assets Ratio
0.02%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$418.95M
Debt to Assets Ratio
0.07%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$435.61M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$416.27M
Debt to Assets Ratio
0.35%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| ARS Pharmaceuticals, Inc. (SPRY) | $426.51M | 68.78% | 26.54% | 0.16% | 5.78% |
| NeoGenomics, Inc. (NEO)vs › | $424.10M | 0.33% | N/A | N/A | N/A |
| Tectonic Therapeutic, Inc. (TECX)vs › | $422.86M | 0.02% | N/A | N/A | N/A |
| Tilray Brands, Inc. (TLRY)vs › | $422.72M | 0.17% | N/A | N/A | N/A |
| NeuroPace, Inc. (NPCE)vs › | $431.97M | 0.72% | N/A | N/A | N/A |
| Prothena Corporation plc (PRTA)vs › | $419.87M | 0.02% | N/A | N/A | N/A |
| Editas Medicine, Inc. (EDIT)vs › | $418.95M | 0.07% | N/A | N/A | N/A |
| YD Bio Limited Ordinary Shares (YDES)vs › | $435.61M | 0.00% | N/A | N/A | N/A |
| Senseonics Holdings, Inc. (SENS)vs › | $416.27M | 0.35% | N/A | N/A | N/A |
| Rezolute, Inc. (RZLT)vs › | $415.98M | 0.01% | N/A | N/A | N/A |
Debt/Assets
68.8%
Debt/Equity
13.72
Current Ratio
3.48
Interest Coverage
-69.0x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 68.78% |
| 2026-03-31 | 33.56% |
| 2025-12-31 | 29.41% |
| 2025-09-30 | 0.41% |
| 2025-06-30 | 0.53% |
| 2025-03-31 | 0.02% |
| 2024-12-31 | 0.01% |
| 2024-09-30 | 0.05% |
| 2024-06-30 | 0.07% |
| 2024-03-31 | 0.10% |
| 2023-12-31 | 0.12% |
| 2023-09-30 | 0.13% |
| 2023-06-30 | 0.15% |
| 2023-03-31 | 0.16% |
| 2022-12-31 | 0.17% |
| 2022-09-30 | 15.94% |
| 2022-06-30 | 15.75% |
| 2022-03-31 | 1.78% |
| 2021-12-31 | 14.70% |
| 2021-09-30 | 1.75% |
| 2021-06-30 | 0.75% |
| 2021-03-31 | 0.91% |
| 2020-12-31 | 1.03% |
| 2019-12-31 | 99.83% |
